What kind of vaccine is Arexvy?

Arexvy and Abrysvo are both RSV vaccines that are approved for use in adults over the age of 60 to reduce their risk of developing lower respiratory tract disease (LRTD). They are also approved for adults aged 50 through 59 years (Arexvy) or aged 18 through 59 (Abrysvo) with certain chronic medical conditions (such as chronic pulmonary disease, chronic cardiovascular disease, diabetes, chronic kidney or liver disease) that put them at increased risk of LRTD caused by RSV. Abrysvo is also approved for use in pregnant women between 32 through 36 weeks gestation, to protect infants against LRTD from the moment they are born until they are 6 months of age. Arexvy is made by GSK and was approved on May 3, 2023; the first RSV vaccine to be approved for older adults. Abrysvo is made by Pfizer and was approved on May 31, 2023; the second RSV vaccine to be approved for older adults. Continue reading

Just one shot of Arexvy into the deltoid muscle of the upper arm is needed to protect older adults against lower respiratory tract disease (LRTD) caused by the respiratory syncytial virus (RSV). Continue reading

RSV symptoms are runny nose, sore throat, stuffy nose, cough wheezing, headache, and fever for adults and RSV symptoms in the young include decreased activity, irritability, and breathing difficulties.